TrialJournal for immunotherapy of cancer2022

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Douglas G McNeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.